Search Results

Inclusion criteria � Patients aged less than / equal to 12 months and less than 18 years � Histologically confirmed diagnosis of medulloblastoma, rhabdomyosarcoma, neuroblastoma, hepatoblastoma, high-grade glioma, or osteosarcoma, that has progressed despite treatment with standard therapies, or for which no standard treatments are available (patients with brainstem gliomas are excluded from this study). � Adequate Performance Status � Adequate kidney, liver, and bone marrow function � A negative pregnancy test for females, and use of highly effective contraception for males and females � Written informed consent/assent before any study-specific procedures � All patients must consent to provide a tumor sample (archival or fresh). The tumor material submitted for these analyses may have been obtained at any time during the course of the patient's disease. Exclusion criteria: � Systemic anticancer treatment (including biologic therapy/antibodies) within 2 weeks before first dose of study treatment (6 weeks for nitrosourea, mitomycin, and monoclonal antibodies). � Focal radiation therapy within 4 weeks before first dose of study treatment, or full spinal radiotherapy within 3 months of first dose of study treatment. � Investigational agents within 2 weeks or less than / equal to 5x t1/2 (whichever is longer) before starting study drug. � Unresolved toxicity or incomplete recovery from previous surgery, unless agreed by Novartis and the Principal nvestigator (PI) and documented. � Patients receiving treatment with certain medications that are known to interact with LDE225 that cannot be discontinued at least 1 week before start of study therapy, and for the duration of the study. � Patients receiving unstable or increasing doses of corticosteroids. � Patients receiving treatment with enzyme-inducing anticonvulsants that cannot be discontinued at least 1 week before start of study therapy, and for the duration of the study. Patients on non-enzyme-inducing anticonvulsants are eligible. � Major surgery, serious illness, or traumatic injury within 2 weeks of starting study therapy. � Patients anticipated to require major surgery during the first 2 cycles of treatment in this study. � Patients who require a nasogastric tube for drug administration (G-tubes are permitted) � Any concurrent severe and/or uncontrolled medical conditions hat in the investigator's opinion could put the patient at greater risk for treatment-related toxicities or confound the interpretation of clinical outcomes. � Patients who have neuromuscular disorders that are associated with elevated CPK (eg, inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy). � Impaired cardiac function or clinically significant heart disease � Pregnant or breast-feeding females. � Known diagnosis of human immunodeficiency virus (HIV), Hepatitis B or C (testing is not mandatory for study entry). � Impairment of GI function or GI disease (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection) � Patients who in the investigator's opinion may be unwilling, unable, or unlikely to comply with the requirements of the study protocol.